Lilly, Daiichi Sankyo Suspend Enrollment In Phase II Trials Of Prasugrel
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysis of “a number of studies” underlies decision to temporarily suspend enrollment to consider dosing changes for the anti-platelet therapy, Lilly tells “The Pink Sheet” DAILY.